Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced results from a study co-sponsored by InMed and the University of British Columbia. Notably, this study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye resulting in enhanced drug uptake via the cornea and lens. “Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward,” Eric A. Adams, president and CEO of InMed, stated in the news release. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.” Per this morning’s update, the study also validated InMed’s capacity to conduct a wide spectrum of drug development activities, including biosynthesis of a cannabinoid using a novel E. coli-based system, packaging of the cannabinoid as a nanoparticle, formulation of a cannabinoid drug candidate into a novel, tissue specific delivery vehicle and confirmation of drug delivery and diffusion into a target tissue.
To view the full press release, visit http://cnw.fm/l8nlX
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com